We are excited about the start of multi-country Phase II clinical trials for YIV-906 and optimistic about its potential to improve the lives of cancer patients, as well as its vanguard role in possibly ushering in a new era of treatment--a convergence of Western and Eastern medicines""The National Foundation for Cancer Research has long differentiated itself from other organizations through our longstanding commitment to scientists and the flexibility we allow these innovators to explore truly untrodden ground," Dr. Ba continued. "We are very proud of standing firmly with Dr. Cheng in his decades-long quest to apply what he has termed 'WE--Western and Eastern--medicine' to cancer therapeutics."
Sujuan Ba, Ph.D., President and CEO, NFCR
Be the first to rate this article
Posted in: Drug Trial News | Medical Condition News
Tags: AIDS, Bioinformatics, Cancer, Cell, Chemotherapy, Clinical Trial, Colorectal, Cytomegalovirus, Drug Disco欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |